Denali Therapeutics Inc. (DNLI) Revenue History
Annual and quarterly revenue from 2015 to present
DNLI Revenue Over Time (2015–2025)
DNLI Revenue Growth History
3 of 6 years with positive growth- FY2015 revenue growth
- N/A
- FY2016 revenue growth
- N/A
- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- -79.3%
- FY2020 revenue growth
- +1158.2%
- FY2021 revenue growth
- -85.5%
- FY2022 revenue growth
- +122.9%
- FY2023 revenue growth
- +204.7%
- FY2024 revenue growth
- -100.0%
- FY2025 revenue growth
- N/A
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $0 | — |
| Q4 2025 | $0 | — |
| Q3 2025 | $0 | — |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $0 | -100.0% |
| Q2 2024 | $0 | -100.0% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2020)
DNLI's revenue distribution by segment and geography for fiscal year 2020
By Product/Segment
DNLI Revenue Analysis (2015–2025)
Current Revenue & Growth
As of June 23, 2026, Denali Therapeutics Inc. (DNLI) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q1 2026) recorded $0 in revenue
Historical Growth Trajectory
DNLI's historical revenue data shows various trends over time. Denali Therapeutics Inc.'s highest annual revenue of $335.7 million was recorded in 2020.
Revenue by Segment
DNLI's revenue is primarily driven by Alzheimer's Disease Services (100%). With over half of revenue concentrated in Alzheimer's Disease Services, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including ARVN (-79.1% YoY), RCUS (+67.4% YoY), and KYMR (-12.6% YoY). Compare DNLI vs ARVN →
DNLI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DNLICurrent | $0 | - | - | - | |
 ARVN | $263M | -79.1% | +58.9% | -43.8% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 PTGX | $46M | -91.5% | +10.0% | -343.6% |
DNLI Historical Revenue Data (2015–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | - | $-11,183,000 | - | $-555,342,000 | - |
| 2024 | $0 | -100.0% | $0 | - | $-487,341,000 | - |
| 2023 | $330.5M | +204.7% | $330.5M | 100.0% | $-196,699,000 | -59.5% |
| 2022 | $108.5M | +122.9% | $108.5M | 100.0% | $-340,744,000 | -314.2% |
| 2021 | $48.7M | -85.5% | $48.7M | 100.0% | $-295,751,000 | -607.8% |
| 2020 | $335.7M | +1158.2% | $335.7M | 100.0% | $62.7M | 18.7% |
| 2019 | $26.7M | -79.3% | $26.7M | 100.0% | $-213,184,000 | -799.1% |
| 2018 | $129.2M | - | $129.2M | 100.0% | $-46,372,000 | -35.9% |
| 2017 | $0 | - | $-3,082,000 | - | $-90,140,000 | - |
| 2016 | $0 | - | $-1,469,000 | - | $-87,433,000 | - |
| 2015 | $0 | - | $-121,000 | - | $-16,679,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DNLI — Frequently Asked Questions
Quick answers to the most common questions about buying DNLI stock.
Is DNLI's revenue growth accelerating or slowing?
DNLI TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is DNLI's revenue history from 2015 to 2026?
Denali Therapeutics Inc. (DNLI) revenue history spans 2015 to 2026. TTM revenue as of 2026 is $0.00, growing at N/A YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is DNLI's long-term revenue growth rate (CAGR)?
Denali Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of N/A is in line with this long-term average. CAGR is the most reliable measure of sustained revenue momentum for DNLI.
Why does DNLI's quarterly revenue fluctuate?
DNLI quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Denali Therapeutics Inc.'s revenue data from 2015 to 2026 shows full historical quarterly detail on this page.
How is DNLI's revenue distributed by segment?
DNLI reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does DNLI's revenue compare to industry peers?
Denali Therapeutics Inc. (DNLI) with TTM revenue of $0.00 and N/A YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.